Synergy of 1,25‑dihydroxyvitamin D3 and carboplatin in growth suppression of SKOV‑3 cells

Zhang,Zengli; Zhang,Hemei; Hu,Zhiyong; Wang,Ping; Wan,Jianmei; Li,Bingyan

doi:10.3892/ol.2014.2307

Synergy of 1,25‑dihydroxyvitamin D3 and carboplatin in growth suppression of SKOV‑3 cells

Authors:
- Zengli Zhang
- Hemei Zhang
- Zhiyong Hu
- Ping Wang
- Jianmei Wan
- Bingyan Li
View Affiliations

Affiliations: Department of Toxicology, School of Public Health, Soochow University, Suzhou, Jiangsu 215123, P.R. China, Li Shui Center for Disease Control and Prevention, Lishui, Zhejiang 323000, P.R. China
Published online on: July 2, 2014 https://doi.org/10.3892/ol.2014.2307
Pages: 1348-1354

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

1α,25-Dihydroxyvitamin D3 [1,25(OH)2D3] has been demonstrated to inhibit the growth of cancer cells. However, carboplatin is the most widely used chemotherapeutic agent to treat cancer. We hypothesized that vitamin D may enhance the antiproliferative effects of carboplatin, and tested this hypothesis in ovarian cancer SKOV‑3 cells treated with carboplatin and 1,25(OH)2D3. Cell viability was determined by Cell Counting Kit‑8, while cell cycle distribution, apoptosis, reactive oxygen species (ROS) and mitochondrial membrane potential (MMP) were analyzed by flow cytometry. In these experiments, 1,25(OH)2D3 and carboplatin each provided dose‑dependent suppression of SKOV‑3 growth, and synergy was demonstrated between 10 nM 1,25(OH)2D3 and carboplatin. The proportion of cells in G0/G1 phase was markedly reduced by the drug combination, while the proportion of cells in G2/M phase was increased. Apoptosis did not increase in ovarian cancer cells treated with 10 nM 1,25(OH)2D3 alone; however, 1,25(OH)2D3 evidently enhanced carboplatin‑induced apoptosis. Similarly, ROS production was evidently higher and MMP was lower in cells treated with the two drugs than in those treated with each drug alone. The results suggested that 1,25(OH)2D3 suppresses SKOV‑3 growth and enhances the antiproliferative effect of carboplatin. The drugs function synergistically by inducing cell cycle arrest, increasing apoptosis and ROS production, and reducing MMP.

View Figures

View References

1	Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2007. CA Cancer J Clin. 57:43–66. 2007.
2	McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 334:1–6. 1996.
3	Ozols RF, Bundy BN, Greer BE, et al; Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 21:3194–3200. 2003.
4	Mutch DG: Gemcitabine combination chemotherapy of ovarian cancer. Gynecol Oncol. 90:S16–S20. 2003.
5	Ozols RF: Systemic therapy for ovarian cancer: current status and new treatments. Semin Oncol. 33(Suppl 6): S3–S11. 2006.
6	Bookman MA, Brady MF, McGuire WP, et al: Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 27:1419–1425. 2009.
7	Stordal B, Pavlakis N and Davey R: A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship. Cancer Treat Rev. 33:688–703. 2007.
8	Markman M, Webster K, Zanotti K, et al: Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials. Gynecol Oncol. 93:699–701. 2004.
9	Pavelka M, Lucas M and Russo N: On the hydrolysis mechanism of the second-generation anticancer drug carboplatin. Chemistry. 13:10108–10116. 2007.
10	Agarwal R and Kaye SB: Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 3:502–516. 2003.
11	Cheng TC, Manorek G, Samimi G, et al: Identification of genes whose expression is associated with cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol. 58:384–395. 2006.
12	Rabik CA and Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 33:9–23. 2007.
13	Roberts D, Schick J, Conway S, et al: Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells. Br J Cancer. 92:1149–1158. 2005.
14	Peters D, Freund J and Ochs RL: Genome-wide transcriptional analysis of carboplatin response in chemosensitive and chemoresistant ovarian cancer cells. Mol Cancer Ther. 4:1605–1616. 2005.
15	Johnatty SE, Beesley J, Paul J, et al: ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. Clin Cancer Res. 14:5594–5601. 2008.
16	Walters MR: Newly identified actions of the vitamin D endocrine system. Endocrinol Rev. 13:719–764. 1992.
17	Saunders DE, Christensen C, Williams JR, et al: Inhibition of breast and ovarian carcinoma cell growth by 1,25-dihydroxyvitamin D3 combined with retinoic acid or dexamethasone. Anticancer Drugs. 6:562–569. 1995.
18	Majewski S, Szmurlo A, Marczak M, et al: Inhibition of tumor cell-induced angiogenesis by retinoids, 1,25-dihydroxyvitamin D3 and their combination. Cancer Lett. 75:35–39. 1993.
19	Koli K and Keski-Oja J: 1alpha,25-dihydroxyvitamin D3 and its analogues down-regulate cell invasion-associated proteases in cultured malignant cells. Cell Growth Differ. 11:221–229. 2000.
20	Evans SR, Shchepotin EI, Young H, et al: 1,25-dihydroxyvitamin D3 synthetic analogs inhibit spontaneous metastases in a 1,2-dimethylhydrazine-induced colon carcinogenesis model. Int J Oncol. 16:1249–1254. 2000.
21	Peterlik M, Grant WB and Cross HS: Calcium, vitamin D and cancer. Anticancer Res. 29:3687–3698. 2009.
22	Akhter J, Chen X, Bowrey P, et al: Vitamin D3 analog, EB1089, inhibits growth of subcutaneous xenographs of the human colon cancer cell line, LoVo, in nude mouse model. Dis Colon Rectum. 40:317–321. 1997.
23	VanWeelden KV, Flanagan L, Binderup L, et al: Apoptotic regression of MCF-7 xenografts in nude mice treated with the vitamin D3 analog, EB1089. Endocrinology. 139:2102–2110. 1998.
24	Mehta RG and Mehta RR: Vitamin D and cancer. J Nutr Biochem. 13:252–264. 2002.
25	Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55. 1984.
26	Soriano AF, Helfrich B, Chan DC, et al: Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res. 59:6178–6184. 1999.
27	Smiley ST, Reers M, Mottola-Hartshorn C, et al: Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. Proc Natl Acad Sci USA. 88:3671–3675. 1991.
28	Sung DK, Chang YS, Kang S, et al: Comparative evaluation of hypoxic-ischemic brain injury by flow cytometric analysis of mitochondrial membrane potential with JC-1 in neonatal rats. J Neurosci Methods. 193:232–238. 2010.
29	Turturro F, Friday E and Welbourne T: Hyperglycemia regulates thioredoxin-ROS activity through induction of thioredoxin-interacting protein (TXNIP) in metastatic breast cancer-derived cells MDA-MB-231. BMC Cancer. 7:962007.
30	Johnson JA, Grande JP, Windebank AJ and Kumar R: 1,25-Dihydroxyvitamin D(3) receptors in developing dorsal root ganglia of fetal rats. Brain Res Dev Brain Res. 92:120–124. 1996.
31	Dokoh S, Donaldson CA, Marion SL, et al: The ovary: a target organ for 1,25-dihydroxyvitamin D3. Endocrinology. 112:200–206. 1983.
32	Ahonen MH, Zhuang YH, Aine R, et al: Androgen receptor and vitamin D receptor in human ovarian cancer: growth stimulation and inhibition by ligands. Int J Cancer. 86:40–46. 2000.
33	Saunders DE, Christensen C, Lawrence WD, et al: Receptors for 1,25-dihydroxyvitamin D3 in gynecologic neoplasms. Gynecol Oncol. 44:131–136. 1992.
34	Garland CF, Garland FC, Gorham ED, et al: The role of vitamin D in cancer prevention. Am J Public Health. 96:252–261. 2006.
35	Grant WB: An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. Cancer. 94:1867–1875. 2002.
36	Bidoli E, La Vecchia C, Talamini R, et al: Micronutrients and ovarian cancer: a case-control study in Italy. Ann Oncol. 12:1589–1593. 2001.
37	Salazar-Martinez E, Lazcano-Ponce EC, Gonzalez Lira-Lira G, et al: Nutritional determinants of epithelial ovarian cancer risk: a case-control study in Mexico. Oncology. 63:151–157. 2002.
38	Moffatt KA, Johannes W and Miller GJ: 1Alpha,25dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines. Clin Cancer Res. 5:695–703. 1999.
39	Jiang F, Li P, Fornace AJ Jr, et al: G2/M arrest by 1,25-dihydroxyvitamin D3 in ovarian cancer cells mediated through the induction of GADD45 via an exhonic enhancer. J Biol Chem. 278:48030–48040. 2003.
40	Li P, Li C, Zhao X, et al: p27(Kip1) stabilization and G(1) arrest by 1,25-dihydroxyvitamin D(3) in ovarian cancer cells mediated through down-regulation of cyclin E/cyclin-dependent kinase 2 and Skp1-Cullin-F-box protein/Skp2 ubiquitin ligase. J Biol Chem. 279:25260–25267. 2004.
41	Cho YL, Christensen C, Saunders DE, et al: Combined effects of 1,25-dihydroxyvitamin D3 and platinum drugs on the growth of MCF-7 cells. Cancer Res. 51:2848–2853. 1991.
42	Light BW, Yu W, McElwain MC, et al: Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma system. Cancer Res. 57:3759–3764. 1997.
43	Koren R, Hadari-Naor I, Zuck E, et al: Vitamin D is a prooxidant in breast cancer cells. Cancer Res. 61:1439–1444. 2001.
44	Wiseman H: Vitamin D is a membrane antioxidant. Ability to inhibit iron-dependent lipid peroxidation in liposomes compared to cholesterol, ergosterol and tamoxifen and relevance to anticancer action. FEBS Lett. 326:285–288. 1993.
45	Poulsen HE, Prieme H and Loft S: Role of oxidative DNA damage in cancer initiation and promotion. Eur J Cancer Prev. 7:9–16. 1998.
46	Marchionatti AM, Picotto G, Narvaez CJ, et al: Antiproliferative action of menadione and 1,25(OH)₂D₃ on breast cancer cells. J Steroid Biochem Mol Biol. 113:227–232. 2009.
47	Koren R, Rocker D, Kotestiano O, et al: Synergistic anticancer activity of 1,25-dihydroxyvitamin D(3) and immune cytokines: the involvement of reactive oxygen species. J Steroid Biochem Mol Biol. 73:105–112. 2000.
48	Bao BY, Ting HJ, Hsu JW and Lee YF: Protective role of 1 alpha, 25-dihydroxyvitamin D3 against oxidative stress in nonmalignant human prostate epithelial cells. Int J Cancer. 122:2699–2706. 2008.
49	Chen WJ, Huang YT, Wu ML, et al: Induction of apoptosis by vitamin D2, ergocalciferol, via reactive oxygen species generation, glutathione depletion, and caspase activation in human leukemia cells. J Agric Food Chem. 56:2996–3005. 2008.
50	Weitsman GE, Ravid A, Liberman UA and Koren R: Vitamin D enhances caspase-dependent and independent TNF-induced breast cancer cell death: the role of reactive oxygen species. Ann N Y Acad Sci. 1010:437–440. 2003.
51	Weitsman GE, Koren R, Zuck E, et al: Vitamin D sensitizes breast cancer cells to the action of H2O2: mitochondria as a convergence point in the death pathway. Free Radic Biol Med. 39:266–278. 2005.
52	Jiang F, Bao J, Li P, et al: Induction of ovarian cancer cell apoptosis by 1,25-Dihydroxyvitamin D3 through the down-regulation of telomerase. J Biol Chem. 279:53213–53221. 2004.